Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group Limited reported its interim results for the half-year ended 31 December 2024, showing a 13% increase in revenue from ordinary activities compared to the previous year. Despite this revenue growth, the company experienced a loss from continuing operations after income tax, although the loss was significantly reduced by 72% compared to the previous year. The results indicate ongoing challenges in profitability, but also show improvement in financial performance, which may impact stakeholders’ confidence and the company’s market positioning.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceuticals. The company is known for its diverse range of products and services, catering to various therapeutic areas and maintaining a significant presence in the global market.
YTD Price Performance: 59.03%
Average Trading Volume: 2,434
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $371.1M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.